ArticleParasites & vectors2021
Molecular characterization and immune protection of the 3-hydroxyacyl-CoA dehydrogenase gene in Echinococcus granulosus.
Article in Parasites & vectors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- EgLDH as a Novel Target: Design and Preliminary Efficacy Assessment of a DNA Vaccine.Animals : an open access journal from MDPI · 2026Article
- Effect of antiserum against recombinant EGr_09888 on the in vitro development of Echinococcus granulosus protoscoleces.Parasitology research · 2025Article
- Oral administration of recombinant Bacillus subtilis spores induces protective immunity against Echinococcus granulosus infection in dogs.Parasites & vectors · 2025Article
- Article
- Cocktail vaccine induces immunoprotection and modulates the fecal microbiota in dogs against Echinococcus granulosus infection.NPJ vaccines · 2025Article
- Integrative Utilization of Transcriptomics and Metabolomics Sheds Light on Disparate Growth Performance of Whiteleg Shrimp,International journal of molecular sciences · 2025Article
- Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts.Parasites & vectors · 2024Review
- RNA sequencing reveals dynamic expression of genes related to innate immune responses in canine small intestinal epithelial cells induced byFrontiers in veterinary science · 2024Article
- Evaluation of protective immune responses induced by DNA vaccines encodingFrontiers in veterinary science · 2024Article
- Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs.PLoS neglected tropical diseases · 2023Article
- Article
- Identification ofFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCystic echinococcosis (CE) is a serious parasitic zoonosis caused by the larvae of the tapeworm Echinococcus granulosus. The development of an effective vaccine is one of the most promising strategies for controlling CE.
methodsThe E. granulosus 3-hydroxyacyl-CoA dehydrogenase (EgHCDH) gene was cloned and expressed in Escherichia coli. The distribution of EgHCDH in protoscoleces (PSCs) and adult worms was analyzed using immunofluorescence. The transcript levels of EgHCDH in PSCs and adult worms were analyzed using quantitative real-time reverse transcription PCR (RT-qPCR). The immune protective effects of the rEgHCDH were evaluated.
resultsThe 924-bp open reading frame sequence of EgHCDH, which encodes a protein of approximately 34 kDa, was obtained. RT-qPCR analysis revealed that EgHCDH was expressed in both the PSCs and adult worms of E. granulosus. Immunofluorescence analysis showed that EgHCDH was mainly localized in the tegument of PSCs and adult worms. Western blot analysis showed that the recombinant protein was recognized by E. granulosus-infected dog sera. Animal challenge experiments demonstrated that dogs immunized with recombinant (r)EgHCDH had significantly higher serum IgG, interferon gamma and interleukin-4 concentrations than the phosphate-buffered saline (PBS) control group. The rEgHCDH vaccine was able to significantly reduce the number of E. granulosus and inhibit the segmental development of E. granulosus compared to the PBS control group.
conclusionsThe results suggest that rEgHCDH can induce partial immune protection against infection with E. granulosus and could be an effective candidate for the development of new vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.